Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

The FDA is warning patients about “counterfeit” Ozempic. Drug manufacturer Novo Nordisk seized “several hundred units” from ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...